AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. VTAK
  4. [8-K] Catheter Precision, Inc. Reports Material Event

[8-K] Catheter Precision, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Catheter Precision, Inc. implemented a 1-for-19 reverse stock split of its common stock after stockholder authorization, effective at 12:01 a.m. ET on August 15, 2025. The company combined every 19 issued shares into one share and reduced issued and outstanding common shares from approximately 23,327,516 to approximately 1,227,764. The common stock continues to trade under the symbol VTAK on the NYSE American on a split-adjusted basis and received a new CUSIP number.

Authorized capital remains unchanged at 10 million preferred and 60 million common shares. Proportionate adjustments were made to outstanding stock options, warrants, conversion prices and shares available under incentive plans. Fractional shares will not be issued; holders entitled to fractions will receive cash pro rata from aggregated fractional-share sales, net of customary fees.

Catheter Precision, Inc. ha effettuato uno split inverso 1-per-19 delle proprie azioni ordinarie, con l'autorizzazione degli azionisti, con efficacia alle 12:01 a.m. ET del 15 agosto 2025. La societ脿 ha raggruppato ogni 19 azioni in circolazione in un'unica azione, riducendo le azioni ordinarie emesse e in circolazione da circa 23.327.516 a circa 1.227.764. Le azioni ordinarie continuano a essere negoziate con il simbolo VTAK sulla NYSE American su base rettificata per lo split e hanno ricevuto un nuovo numero CUSIP.

Il capitale autorizzato rimane invariato a 10 milioni di azioni privilegiate e 60 milioni di azioni ordinarie. Sono stati effettuati adeguamenti proporzionali alle opzioni su azioni, ai warrant, ai prezzi di conversione e alle azioni disponibili nei piani incentivanti in essere. Non saranno emesse frazioni di azioni; i detentori aventi diritto a frazioni riceveranno una liquidazione in contanti proporzionale derivante dalla vendita aggregata delle frazioni, al netto delle commissioni consuete.

Catheter Precision, Inc. llev贸 a cabo una consolidaci贸n inversa de acciones de 1 por 19 de sus acciones ordinarias, tras la autorizaci贸n de los accionistas, con vigencia a las 12:01 a.m. ET del 15 de agosto de 2025. La compa帽铆a combin贸 cada 19 acciones emitidas en una sola, reduciendo las acciones ordinarias emitidas y en circulaci贸n de aproximadamente 23.327.516 a aproximadamente 1.227.764. Las acciones ordinarias contin煤an cotizando con el s铆mbolo VTAK en la NYSE American en base ajustada por la consolidaci贸n y recibieron un nuevo n煤mero CUSIP.

El capital autorizado permanece sin cambios en 10 millones de acciones preferentes y 60 millones de acciones ordinarias. Se realizaron ajustes proporcionales a las opciones sobre acciones, warrants, precios de conversi贸n y acciones disponibles bajo los planes de incentivos. No se emitir谩n fracciones de acciones; los titulares con derecho a fracciones recibir谩n efectivo prorrateado procedente de la venta agregada de las fracciones, neto de las tarifas habituales.

Catheter Precision, Inc.電� 欤检＜ 鞀轨澑 頉� 2025雲� 8鞗� 15鞚� 氙戈淡 霃欕秬鞁滉皠(ET) 鞓れ爠 12鞁� 01攵勲秬搿� 氤错喌欤检棎 雽�頃� 1雽� 19鞚� 鞎‰┐氤戫暕(鞐硲頃�)鞚� 鞁滍枆頄堨姷雼堧嫟. 須岇偓電� 氚滍枆霅� 19欤茧雼� 1欤茧 氤戫暕頃橃棳 氚滍枆 氚� 鞙犿喌 氤错喌欤� 靾橂ゼ 鞎� 23,327,516欤检棎靹� 鞎� 1,227,764欤茧 臧愳唽鞁滌及鞀惦媹雼�. 氤错喌欤茧姅 氤戫暕 臁办爼 旮办鞙茧 NYSE American鞐愳劀 瓿勳啀 VTAK 旮绊樃搿� 瓯半灅霅橂┌ 靸堧鞖� CUSIP 氩堩樃毳� 攵�鞐皼鞎橃姷雼堧嫟.

項堦皜霅� 鞛愲掣鞚� 鞖办劆欤� 1,000毵� 欤� 氚� 氤错喌欤� 6,000毵� 欤茧 氤�霃欖澊 鞐嗢姷雼堧嫟. 氙戈舶鞝� 鞀ろ啞鞓奠厴, 鞗岆煱韸�, 鞝勴櫂臧� 氚� 鞚胳劶韹半笇 頂岆灉鞐� 霐半澕 靷毄 臧�電ロ暅 欤检嫕鞐� 牍勲 臁办爼鞚� 鞚措（鞏挫鞀惦媹雼�. 靻岇垬欤检嫕鞚� 氚滍枆霅橃 鞎婌溂氅�, 靻岇垬欤检棎 雽�頃� 甓岆Μ臧� 鞛堧姅 氤挫湢鞛愲姅 韱奠儊 靾橃垬耄岆ゼ 瓿奠牅頃� 歆戧硠霅� 靻岇垬欤� 毵り皝雽�旮堨棎靹� 牍勲 氚半秳霅� 順勱笀鞚� 歆�旮夒皼瓴� 霅╇媹雼�.

Catheter Precision, Inc. a r茅alis茅 un regroupement d'actions (reverse split) au ratio de 1 pour 19 de ses actions ordinaires, apr猫s autorisation des actionnaires, effectif 脿 00h01 ET le 15 ao没t 2025. La soci茅t茅 a combin茅 chaque groupe de 19 actions 茅mises en une seule action, r茅duisant le nombre d'actions ordinaires 茅mises et en circulation d'environ 23 327 516 脿 environ 1 227 764. Les actions ordinaires continuent d'锚tre n茅goci茅es sous le symbole VTAK sur la NYSE American sur une base ajust茅e du regroupement et ont re莽u un nouveau num茅ro CUSIP.

Le capital autoris茅 reste inchang茅 脿 10 millions d'actions privil茅gi茅es et 60 millions d'actions ordinaires. Des ajustements proportionnels ont 茅t茅 effectu茅s sur les options d'achat d'actions en circulation, les bons de souscription, les prix de conversion et les actions disponibles dans le cadre des plans d'incitation. Les fractions d'actions ne seront pas 茅mises ; les titulaires ayant droit 脿 des fractions recevront en esp猫ces une part au prorata issue de la vente group茅e des fractions, nets des frais usuels.

Catheter Precision, Inc. f眉hrte nach Aktion盲rsgenehmigung eine 1-zu-19-Aktienzusammenlegung (Reverse Stock Split) ihrer Stammaktien mit Wirkung ab 15. August 2025, 0:01 Uhr ET durch. Das Unternehmen fasste jeweils 19 ausgegebene Aktien zu einer Aktie zusammen und reduzierte die ausgegebenen und im Umlauf befindlichen Stammaktien von etwa 23.327.516 auf etwa 1.227.764. Die Stammaktien werden weiterhin unter dem K眉rzel VTAK an der NYSE American auf splitbereinigter Basis gehandelt und erhielten eine neue CUSIP-Nummer.

Das genehmigte Kapital bleibt unver盲ndert bei 10 Millionen Vorzugs- und 60 Millionen Stammaktien. Proportionale Anpassungen wurden an ausstehenden Aktienoptionen, Warrants, Umrechnungspreisen und den im Rahmen von Incentive-Pl盲nen verf眉gbaren Aktien vorgenommen. Bruchst眉cke von Aktien werden nicht ausgegeben; Inhaber mit Anspruch auf Bruchteile erhalten anteiligen Barbetrag aus dem aggregierten Verkauf der Bruchteile, abz眉glich 眉blicher Geb眉hren.

Positive
  • Reverse split implemented at a 1-for-19 ratio, reducing outstanding shares from approximately 23,327,516 to 1,227,764
  • Listing continuity: Common stock continues to trade under the existing symbol "VTAK" on the NYSE American on a split-adjusted basis
  • Proportional adjustments were made to outstanding stock options, warrants, preferred conversion terms, and incentive-plan share availability to reflect the Reverse Stock Split
  • Authorized capital unchanged, maintaining 10 million preferred and 60 million common shares
Negative
  • None.

Insights

TL;DR Routine charter amendment to consolidate shares via a 1-for-19 reverse split, preserving capital structure while retaining listing.

The board executed its previously authorized discretion to amend the charter and effect a 1-for-19 reverse stock split, which uniformly consolidates outstanding shares and keeps the company listed under the existing trading symbol. The action required and received stockholder approval and was implemented via a Delaware certificate of amendment. The amendment leaves authorized share counts unchanged and includes standard mechanics for fractional-share cash-out and proportional adjustments to equity-linked instruments.

TL;DR Share count materially reduced from ~23.3M to ~1.23M via 1-for-19 reverse split; equity-linked instruments adjusted proportionally.

This reverse split reduces the number of outstanding shares reported and may affect per-share metrics going forward because share denominators are smaller, though the company notes no change to authorized capital. The company updated registration statements to reflect the split-adjusted share counts and confirmed treatment for fractional shares and adjustments to options, warrants and preferred conversions. There is no disclosure here of cash-raising or changes to business operations.

Catheter Precision, Inc. ha effettuato uno split inverso 1-per-19 delle proprie azioni ordinarie, con l'autorizzazione degli azionisti, con efficacia alle 12:01 a.m. ET del 15 agosto 2025. La societ脿 ha raggruppato ogni 19 azioni in circolazione in un'unica azione, riducendo le azioni ordinarie emesse e in circolazione da circa 23.327.516 a circa 1.227.764. Le azioni ordinarie continuano a essere negoziate con il simbolo VTAK sulla NYSE American su base rettificata per lo split e hanno ricevuto un nuovo numero CUSIP.

Il capitale autorizzato rimane invariato a 10 milioni di azioni privilegiate e 60 milioni di azioni ordinarie. Sono stati effettuati adeguamenti proporzionali alle opzioni su azioni, ai warrant, ai prezzi di conversione e alle azioni disponibili nei piani incentivanti in essere. Non saranno emesse frazioni di azioni; i detentori aventi diritto a frazioni riceveranno una liquidazione in contanti proporzionale derivante dalla vendita aggregata delle frazioni, al netto delle commissioni consuete.

Catheter Precision, Inc. llev贸 a cabo una consolidaci贸n inversa de acciones de 1 por 19 de sus acciones ordinarias, tras la autorizaci贸n de los accionistas, con vigencia a las 12:01 a.m. ET del 15 de agosto de 2025. La compa帽铆a combin贸 cada 19 acciones emitidas en una sola, reduciendo las acciones ordinarias emitidas y en circulaci贸n de aproximadamente 23.327.516 a aproximadamente 1.227.764. Las acciones ordinarias contin煤an cotizando con el s铆mbolo VTAK en la NYSE American en base ajustada por la consolidaci贸n y recibieron un nuevo n煤mero CUSIP.

El capital autorizado permanece sin cambios en 10 millones de acciones preferentes y 60 millones de acciones ordinarias. Se realizaron ajustes proporcionales a las opciones sobre acciones, warrants, precios de conversi贸n y acciones disponibles bajo los planes de incentivos. No se emitir谩n fracciones de acciones; los titulares con derecho a fracciones recibir谩n efectivo prorrateado procedente de la venta agregada de las fracciones, neto de las tarifas habituales.

Catheter Precision, Inc.電� 欤检＜ 鞀轨澑 頉� 2025雲� 8鞗� 15鞚� 氙戈淡 霃欕秬鞁滉皠(ET) 鞓れ爠 12鞁� 01攵勲秬搿� 氤错喌欤检棎 雽�頃� 1雽� 19鞚� 鞎‰┐氤戫暕(鞐硲頃�)鞚� 鞁滍枆頄堨姷雼堧嫟. 須岇偓電� 氚滍枆霅� 19欤茧雼� 1欤茧 氤戫暕頃橃棳 氚滍枆 氚� 鞙犿喌 氤错喌欤� 靾橂ゼ 鞎� 23,327,516欤检棎靹� 鞎� 1,227,764欤茧 臧愳唽鞁滌及鞀惦媹雼�. 氤错喌欤茧姅 氤戫暕 臁办爼 旮办鞙茧 NYSE American鞐愳劀 瓿勳啀 VTAK 旮绊樃搿� 瓯半灅霅橂┌ 靸堧鞖� CUSIP 氩堩樃毳� 攵�鞐皼鞎橃姷雼堧嫟.

項堦皜霅� 鞛愲掣鞚� 鞖办劆欤� 1,000毵� 欤� 氚� 氤错喌欤� 6,000毵� 欤茧 氤�霃欖澊 鞐嗢姷雼堧嫟. 氙戈舶鞝� 鞀ろ啞鞓奠厴, 鞗岆煱韸�, 鞝勴櫂臧� 氚� 鞚胳劶韹半笇 頂岆灉鞐� 霐半澕 靷毄 臧�電ロ暅 欤检嫕鞐� 牍勲 臁办爼鞚� 鞚措（鞏挫鞀惦媹雼�. 靻岇垬欤检嫕鞚� 氚滍枆霅橃 鞎婌溂氅�, 靻岇垬欤检棎 雽�頃� 甓岆Μ臧� 鞛堧姅 氤挫湢鞛愲姅 韱奠儊 靾橃垬耄岆ゼ 瓿奠牅頃� 歆戧硠霅� 靻岇垬欤� 毵り皝雽�旮堨棎靹� 牍勲 氚半秳霅� 順勱笀鞚� 歆�旮夒皼瓴� 霅╇媹雼�.

Catheter Precision, Inc. a r茅alis茅 un regroupement d'actions (reverse split) au ratio de 1 pour 19 de ses actions ordinaires, apr猫s autorisation des actionnaires, effectif 脿 00h01 ET le 15 ao没t 2025. La soci茅t茅 a combin茅 chaque groupe de 19 actions 茅mises en une seule action, r茅duisant le nombre d'actions ordinaires 茅mises et en circulation d'environ 23 327 516 脿 environ 1 227 764. Les actions ordinaires continuent d'锚tre n茅goci茅es sous le symbole VTAK sur la NYSE American sur une base ajust茅e du regroupement et ont re莽u un nouveau num茅ro CUSIP.

Le capital autoris茅 reste inchang茅 脿 10 millions d'actions privil茅gi茅es et 60 millions d'actions ordinaires. Des ajustements proportionnels ont 茅t茅 effectu茅s sur les options d'achat d'actions en circulation, les bons de souscription, les prix de conversion et les actions disponibles dans le cadre des plans d'incitation. Les fractions d'actions ne seront pas 茅mises ; les titulaires ayant droit 脿 des fractions recevront en esp猫ces une part au prorata issue de la vente group茅e des fractions, nets des frais usuels.

Catheter Precision, Inc. f眉hrte nach Aktion盲rsgenehmigung eine 1-zu-19-Aktienzusammenlegung (Reverse Stock Split) ihrer Stammaktien mit Wirkung ab 15. August 2025, 0:01 Uhr ET durch. Das Unternehmen fasste jeweils 19 ausgegebene Aktien zu einer Aktie zusammen und reduzierte die ausgegebenen und im Umlauf befindlichen Stammaktien von etwa 23.327.516 auf etwa 1.227.764. Die Stammaktien werden weiterhin unter dem K眉rzel VTAK an der NYSE American auf splitbereinigter Basis gehandelt und erhielten eine neue CUSIP-Nummer.

Das genehmigte Kapital bleibt unver盲ndert bei 10 Millionen Vorzugs- und 60 Millionen Stammaktien. Proportionale Anpassungen wurden an ausstehenden Aktienoptionen, Warrants, Umrechnungspreisen und den im Rahmen von Incentive-Pl盲nen verf眉gbaren Aktien vorgenommen. Bruchst眉cke von Aktien werden nicht ausgegeben; Inhaber mit Anspruch auf Bruchteile erhalten anteiligen Barbetrag aus dem aggregierten Verkauf der Bruchteile, abz眉glich 眉blicher Geb眉hren.

false 0001716621 0001716621 2025-08-13 2025-08-13
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
 
Date of Report (Date of earliest event reported): August 13, 2025
 
Catheter Precision, Inc.
(Exact name of registrant as specified in its charter)
 
 
Delaware
001-38677
38-3661826
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
 
1670 Highway 160 West – Suite 205, Fort Mill, SC 29708
(Address of principal executive offices) (Zip code)
 
Registrant’s telephone number, including area code: (973) 691-2000
 
Not Applicable
(Former name of former address, if changes since last report.)
 
 
Check the appropriate box below if the Form 8‑K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
 
 
☐
Soliciting material pursuant to Rule 14a‑12 under the Exchange Act (17 CFR 240.14a‑12)
   
 
 
☐
Pre-commencement communications pursuant to Rule 14d‑2(b) under the Exchange Act (17 CFR 240.14d‑2(b))
   
 
 
☐
Pre-commencement communications pursuant to Rule 13e‑4(c) under the Exchange Act (17 CFR 240.13e‑4(c))
 
 
Securities registered pursuant to Section 12(b) of the Act:
         
Title of each class
  
Trading Symbol(s)
  
Name of each exchange on which registered
Common Stock
  
VTAK
  
NYSE American
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b‑2 of the Securities Exchange Act of 1934 (§240.12b‑2 of this chapter).
 
Emerging Growth Company         ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.          ☐
 
 
 
 
 
Item 3.03. Material Modification to Rights of Security Holders.
 
To the extent required by Item 3.03 of Form 8-K, the information in Item 5.03 of this report is incorporated herein by reference.
 
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
 
As previously reported in its Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on July 28, 2025, Catheter Precision, Inc. (“we,” “us,” “our” or the “Company”) held its 2025 annual meeting (the “Annual Meeting”) of stockholders on July 25, 2025, at which the Company’s stockholders approved the proposal to give the Company’s board of directors (the “Board”) the authority, at its discretion, to file a certificate of amendment to the Company’s restated certificate of incorporation, as amended, to effect a reverse split of the Company’s issued common stock, par value $0.0001 per share (the “Common Stock”), at a ratio not less than 1-for-5 and not greater than 1-for-19, with the exact ratio to be selected by the Board in its discretion and to be effected, if at all, in the sole discretion of the Board at any time following stockholder approval of the proposal and without further approval or authorization of the Company’s stockholders.
 
Subsequently, the Board determined to effect a reverse split of the Common Stock (the “Reverse Stock Split”) at a ratio of 1-for-19 (the “Reverse Stock Split Ratio”).
 
On August 13, 2025, the Company filed a certificate of amendment to the Company’s restated certificate of incorporation, as amended, with the Secretary of State of the State of Delaware to effect the Reverse Stock Split (the “Charter Amendment”). The Charter Amendment became effective at 12:01 a.m. Eastern Time on August 15, 2025, and the Common Stock began trading on a split-adjusted basis at the opening of trading on the NYSE American on August 15, 2025. The Common Stock will continue to trade under its existing symbol “VTAK,” but the Common Stock has been assigned a new CUSIP number (74933X 708).  Following the Reverse Stock Split, every 19 shares of Common Stock issued, including shares held by the Company in treasury, if any, was automatically reclassified and combined into one share of Common Stock. No fractional shares will be issued to stockholders as a result of the Reverse Stock Split. Stockholders of record who otherwise would be entitled to receive fractional shares will be entitled to receive their pro rata portion of the net proceeds obtained from the aggregation and sale by the exchange agent of the fractional shares resulting from the reverse stock split (reduced by any customary brokerage fees, commissions and other expenses). The Reverse Stock Split affects all stockholders uniformly and will not change any stockholder’s percentage ownership interest or any stockholder’s proportionate voting power, except for immaterial changes that may result from the treatment of fractional shares.
 
The Reverse Stock Split reduced the number of issued and outstanding shares of Common Stock from approximately 23,327,516 to approximately 1,227,764. The Company’s authorized capital stock did not change as a result of the Reverse Stock Split, but remains at 10 million shares of Preferred Stock and 60 million shares of Common Stock.
 
In addition, as a result of the Reverse Stock Split, proportionate adjustments have been made to the per share exercise prices of, and the number of shares underlying, the Company’s outstanding stock options and warrants, as well as to the number of shares available for the grant of awards under the Company’s stock incentive plans. The per share conversion prices and ratios of the Company’s outstanding preferred stock have also adjusted proportionately.
 
The foregoing description of the Charter Amendment does not purport to be complete and is qualified in its entirety by reference to the full text thereof, which is filed as an exhibit to this report and is incorporated herein by reference.
 
-2-
 
 
Item 8.01 Other Events.
 
The information in Item 5.03 of this report is incorporated herein by reference.
 
The Company has registration statements on Form S-1 No. 333-262195, Post Effective Amendment to S-1 No. 333-240187, S-1 No. 333-239887, S-1 No. 333-237701, S-3 No. 333-267443, S-1 (Post Effective Amendment to S-3) No. 333-269491, S-3 No. 333-271388, S-1 (Post Effective Amendment to S-3) No. 333-270919, S-8 No. 333-264495, S-8 No. 333-254370, S-8 No. 333-250094, S-8 No. 333-237096, S-8 No. 333-230332, S-8 No. 333-227696, S-8 No. 333-269612, S-8 No. 333-273351, S-3 No. 333-284217, S-1 No. 333-283392, Post Effective Amendment to S-1 No. 333-281849, S-1 No. 333-279930, S-8 No. 333-280786, S-3 No. 333-287483, and S-8 No. 333-288348 on file with the SEC (collectively, the “Registration Statements”). SEC regulations permit the Company to incorporate by reference future filings made with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, prior to the termination of the offerings covered by these registration statements. The information incorporated by reference is considered part of the prospectus included within each of those registration statements. Information in this Item 8.01 is intended to be automatically incorporated by reference into each of these Registration Statements, thereby amending them. Pursuant to Rule 416(b) under the Securities Act of 1933, as amended, the amount of undistributed shares of Common Stock deemed covered by the Registration Statements was proportionately reduced as of the effective time of the Reverse Stock Split at the Reverse Stock Split Ratio.
 
Item 9.01 Financial Statements and Exhibits.
 
(d) Exhibits.
 
Exhibit No.
  
Description
3.1
  
Certificate of Amendment of Restated Certificate of Incorporation dated August 13, 2025
     
104
  
Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
-3-
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
 
CATHETER PRECISION, INC.
  
     
     
Date: August 15, 2025
/s/ Philip Anderson
  
 
Philip Anderson
  
 
Chief Financial Officer
  
 
 

Source:

FAQ

What reverse split ratio did Catheter Precision (VTAK) implement?

The company effected a 1-for-19 reverse stock split of its common stock, effective August 15, 2025.

How many shares are outstanding after the reverse split for VTAK?

Issued and outstanding shares were reduced to approximately 1,227,764 from about 23,327,516.

Will VTAK continue trading on the NYSE American after the split?

Yes. The common stock began trading on a split-adjusted basis at the opening of trading on the NYSE American on August 15, 2025, under the existing symbol VTAK.

What happens to fractional shares after the reverse split?

No fractional shares will be issued; stockholders entitled to fractional shares will receive a pro rata cash payment from the aggregated sale of fractional shares, net of customary fees.

Did the reverse split change the company鈥檚 authorized share counts?

No. The authorized capital stock remained unchanged at 10 million preferred shares and 60 million common shares.
Stock VTAK logo
Catheter Precision

NYSE:VTAK

VTAK Rankings

#6363 Ranked by Market Cap
N/A Ranked by Dividends
#5 Top Gainer

VTAK Latest News

Aug 18, 2025
Catheter Precision Receives Approval for LockeT in the United Kingdom
Aug 15, 2025
Catheter Precision, Inc. Announces Effectiveness of 1-for-19 Reverse Stock Split
Aug 13, 2025
First LockeT Cases Completed in Germany
Aug 11, 2025
Catheter Precision, Inc. Reports Results of Operations for Second Quarter 2025
Aug 7, 2025
Milestone Achievement for Hospital Using Catheter Precision鈥檚 VIVO System

VTAK Latest SEC Filings

Aug 14, 2025
[SCHEDULE 13G/A] Catheter Precision, Inc. SEC Filing
Aug 14, 2025
[Form 4] Catheter Precision, Inc. Insider Trading Activity
Aug 14, 2025
[Form 4] Catheter Precision, Inc. Insider Trading Activity
Aug 14, 2025
[Form 4] Catheter Precision, Inc. Insider Trading Activity
Aug 11, 2025
[10-Q] Catheter Precision, Inc. Quarterly Earnings Report

VTAK Stock Data

3.98M
609.87k
7.99%
4.89%
2.93%
Medical Devices
Surgical & Medical Instruments & Apparatus
United States
FORT MILL